Reversing Atherosclerosis: Repair Biotechnologies' Novel Approach to Clearing Arterial Plaque
The video features a presentation by Reason, co-founder of Repair Biotechnologies, at the Longevity Summit Dublin 2024. Reason discusses their company's innovative approach to reversing atherosclerosis, a major cause of mortality worldwide. Their therapy uses a fusion protein delivered via mRNA in lipid nanoparticles to clear excess free cholesterol from liver cells. This approach has shown promising results in mouse models, reducing plaque volume by 17% in just 6 weeks, improving cardiovascular function, and stabilizing plaques. Unlike current treatments that mainly slow progression, Repair Biotechnologies' therapy can actually reverse existing plaque buildup.
Reason outlines the company's plans to begin non-human primate studies later in the year, aiming for human trials by early 2026. They intend to initially target homozygous familial hypercholesterolemia, a rare genetic disorder, to potentially gain fast-track FDA approval. The therapy also shows promise for treating other conditions like metabolic dysfunction-associated steatohepatitis (MASH) and potentially neurodegenerative diseases. Reason emphasizes the therapy's wide therapeutic window and its potential to dramatically reduce atherosclerosis-related mortality worldwide. The presentation concludes with a brief overview of the company's team, funding status, and future goals.
▶
